Enanta Pharmaceuticals, Inc.
Spiropyrrolidine derived antiviral agents
Last updated:
Abstract:
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: ##STR00001## which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Status:
Grant
Type:
Utility
Filling date:
20 Sep 2021
Issue date:
10 May 2022